Diagonal Bio has released a white paper detailing the use of LAMPlify™ in the rapid and accurate detection of markers in genetic material. The paper, by Jack Egelund Madsen, CEO of Diagonal Bio AB, details how it can be used to reliably identify genetic markers with the same accuracy as traditional PCR-based tests, but in less time.
The paper also details the first validation study of the LAMPlify™ prototype performed at the externally accredited laboratory Centre for Diagnostics at the Technical University of Denmark (DTU), HealthTech, which made a direct comparison of the technology with that of an accredited PCR-based method for detection of a genetic marker for COVID-19.
You can download the White Paper below.
